Satellos Bioscience Inc.
MSCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $3 | $2 |
| G&A Expenses | $0 | $0 | $5 | $3 |
| SG&A Expenses | $0 | $0 | $5 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | $8 | $5 |
| Operating Income | -$0 | -$0 | -$8 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$3 | -$11 |
| Pre-Tax Income | -$0 | -$0 | -$11 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$11 | -$16 |
| % Margin | – | – | – | – |
| EPS | -0.24 | -0.18 | -0.32 | -0.64 |
| % Growth | -33.3% | 43.8% | 50% | – |
| EPS Diluted | -0.24 | -0.18 | -0.32 | -0.64 |
| Weighted Avg Shares Out | 0 | 0 | 36 | 24 |
| Weighted Avg Shares Out Dil | 0 | 0 | 36 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$8 | -$5 |
| % Margin | – | – | – | – |